Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Might Pentoxifylline Have a Role as Adjuvant Therapy for Patients with Giant Cell Arteritis?

  • 26 Accesses

  • 2 Citations

This is a preview of subscription content, log in to check access.


  1. 1.

    Schmidt J, Warrington KJ. Polymyalgia rheumatica and giant cell arteritis in older patients: diagnosis and pharmacological management. Drugs Aging 2011; 28(8): 651–6

  2. 2.

    Weyand CM, Younge BR, Goronzy JJ. IFN-γ and IL-17: the two faces of T-cell pathology in giant cell arteritis. Curr Opin Rheumatol 2011 Jan; 23(1): 43–9

  3. 3.

    Moller DR, Wysocka M, Greenlee BM, et al. Inhibition of human interleukin-12 production by pentoxifylline. Immunology 1997 Jun; 91(2): 197–203

  4. 4.

    Samardzic T, Jankovic V, Stosic-Grujicic S, et al. Pentoxifylline inhibits the synthesis and IFN-gamma-inducing activity of IL-18. Clin Exp Immunol 2001 May; 124(2): 274–81

Download references


No sources of funding were used to assist in the preparation of this letter. The author has no conflicts of interest that are potentially relevant to the content of this letter.

Author information

Correspondence to Dr Francisco José Fernández-Fernández.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Fernández-Fernández, F.J. Might Pentoxifylline Have a Role as Adjuvant Therapy for Patients with Giant Cell Arteritis?. Drugs Aging 28, 847 (2011).

Download citation


  • Corticosteroid
  • Pentoxifylline
  • Giant Cell Arteritis
  • Polymyalgia Rheumatica
  • Immunological Disorder